Lung DiseasesCaract-AiresNCT03250897
Phenotypic Characterization of Alveolar Macrophages 2016 (Caract-Aires-2016)
An observational study of Lung Diseases, run by Rennes University Hospital at 1 site in France.
Trial summary
The aim of the study is to investigate by flow cytometry the phenotype of alveolar macrophages (AMs) isolated from patients with non-infectious lung diseases. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Diseases
- How many people
- 18 participants
- Where
- 1 siteFrance
- Study dates
- Nov 2016to 1 Dec 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients affected by non-infectious lung diseases older than 18 years
Who may be able to join
- Patients affected by non-infectious lung diseases and for whom a broncho-alveolar lavage is scheduled for their medical care in the pulmonary division
- Patient Information leaflet provided
- Written informed consent of the patient
Who cannot join
- A suspected respiratory infection
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Phenotypic Characterization of Alveolar Macrophages 2016
The aim of the study is to investigate by flow cytometry the phenotype of alveolar macrophages (AMs) isolated from patients with non-infectious lung diseases.
Read the detailed description
Although alveolar macrophages (AMs) represent the main immune cell population in the human lungs, consensus on their phenotypic characterization is still missing.
Current translational protocols use human AMs obtained by invasive methods (broncho-alveolar lavage and lung biopsy) or differentiate macrophages from blood monocytes cultured in the presence of growth factors such as macrophage colony-stimulating factor (M-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF). The group has already published the phenotypic and functional comparison of human blood monocyte-derived macrophages differentiated with M-CSF or GM-CSF. Aim of this study is to use a multi-staining flow cytometry (FACS analysis) to better characterize the phenotype of AMs isolated from broncho-alveolar lavage fluids of patients affected by non-infectious lung diseases. The FACS profiles of AMs will be further compared to the phenotypic profile of blood monocyte-derived macrophages differentiated in the presence of GM-CSF or M-CSF. The results of this study will allow to define the most valid in vitro model of AMs in a non-infectious setting.
- Conditions
- Lung Diseases
- Keywords
- Alveolar macrophages, Blood monocyte-derived macrophages, FACS analysis, Broncho-alveolar lavage fluids, Non-infectious lung diseases
- Medical subject headings
- Lung Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
To investigate by flow cytometry the phenotype of alveolar macrophages (AMs) isolated from broncho-alveolar lavage fluids of patients with non-infectious lung diseases.
Characterization of membrane proteins by multi-staining flow cytometry (FACS analysis)
Measured: 1 year
Secondary outcomes (1)
To compare the phenotypic profile of AMs from broncho-alveolar lavage fluids of patients with non-infectious lung diseases to that of blood monocyte-derived macrophages differentiated in the presence of GM-CSF or M-CSF and obtained from healthy donors
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Aug 2017
- Study startNov 2016
- Primary completion1 Dec 2017
- Study completion1 Dec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung DiseasesStudies of the same condition, open and under way.
- More trials run by Rennes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rennes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Stéphane Jouneau, Professor, Principal investigator, Rennes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03250897
- Sponsor's protocol ID
- 35RC16_3055_Caract-Aires-2016
- Acronym
- Caract-Aires
- Status last verified
- Jun 2026
- First submitted
- 11 Aug 2017
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phenotypic Characterization of Alveolar Macrophages 2016
- ClinicalTrials.gov ID
- NCT03250897
- Acronym / sponsor ID
- Caract-Aires / 35RC16_3055_Caract-Aires-2016
- Conditions
- Lung Diseases
- Keywords
- Alveolar macrophages, Blood monocyte-derived macrophages, FACS analysis, Broncho-alveolar lavage fluids, Non-infectious lung diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- Rennes University HospitalUniversity, hospital or other
- Study start
- Nov 2016 (actual)
- Primary completion
- 1 Dec 2017 (actual)
- Study completion
- 1 Dec 2017 (actual)
- First posted
- 16 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to investigate by flow cytometry the phenotype of alveolar macrophages (AMs) isolated from patients with non-infectious lung diseases.
Detailed description
Although alveolar macrophages (AMs) represent the main immune cell population in the human lungs, consensus on their phenotypic characterization is still missing.
Current translational protocols use human AMs obtained by invasive methods (broncho-alveolar lavage and lung biopsy) or differentiate macrophages from blood monocytes cultured in the presence of growth factors such as macrophage colony-stimulating factor (M-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF). The group has already published the phenotypic and functional comparison of human blood monocyte-derived macrophages differentiated with M-CSF or GM-CSF. Aim of this study is to use a multi-staining flow cytometry (FACS analysis) to better characterize the phenotype of AMs isolated from broncho-alveolar lavage fluids of patients affected by non-infectious lung diseases. The FACS profiles of AMs will be further compared to the phenotypic profile of blood monocyte-derived macrophages differentiated in the presence of GM-CSF or M-CSF. The results of this study will allow to define the most valid in vitro model of AMs in a non-infectious setting.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients affected by non-infectious lung diseases older than 18 years
Key inclusion criteria (3 listed)
- Patients affected by non-infectious lung diseases and for whom a broncho-alveolar lavage is scheduled for their medical care in the pulmonary division
- Patient Information leaflet provided
- Written informed consent of the patient
Key exclusion criteria (1 listed)
- A suspected respiratory infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To investigate by flow cytometry the phenotype of alveolar macrophages (AMs) isolated from broncho-alveolar lavage fluids of patients with non-infectious lung diseases.
Time frame: 1 year
Characterization of membrane proteins by multi-staining flow cytometry (FACS analysis)
1 secondary outcome
To compare the phenotypic profile of AMs from broncho-alveolar lavage fluids of patients with non-infectious lung diseases to that of blood monocyte-derived macrophages differentiated in the presence of GM-CSF or M-CSF and obtained from healthy donors
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
Related trials for Lung Diseases
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stéphane Jouneau, Professor principal investigator
Rennes University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Diseases, run by Rennes University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To investigate by flow cytometry the phenotype of alveolar macrophages (AMs) isolated from broncho-alveolar lavage fluids of patients with non-infectious lung diseases. (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.